patients she has described the microbiological features of
pneumonia in different settings and the risk factors associated with
antibiotic-resistant pathogens she has demonstrated that HIV
patients with Legionella pneumonia should be managed in the
same way as people without HIV and that virologically suppressed
HIV patients with pneumococcal pneumonia should be managed in
the same way as the general population and she has investigated
pneumonia and sepsis in very old patients.
Bin Cao
Bin Cao is Director of the Department of Pulmonary and Critical
Care Medicine, China-Japan Friendship Hospital (Beijing, China),
and a professor at Peking Union Medical College, Capital Medical
University, and Tsinghua University-Peking University Joint Center
for Life Sciences (all Beijing). He is a member of the Chinese
Academy of Medical Sciences, co-founder of CAP-China (https://
www.chinapneumonia.cn/) and President-Elect of Chinese Thoracic
Society (CTS). A physician-scientist, Bin is a leader in the field of
respiratory medicine and a tireless researcher of evidence-based
medicine for respiratory infections.
He pioneered “respiratory viral sepsis”, which extended the theory
of sepsis and initiated the “seven-category ordinal scale” in clinical
trials, which provided the feasibility to conduct randomised
controlled clinical trials during the pandemic. His research has an
outstanding influence in China and has provided a source for the
treatment guidelines of respiratory diseases of the WHO and around
the world.
Bin has published over 200 original peer reviewed articles and
reviews in major journals, including The Lancet and the New
England Journal of Medicine, among which 14 papers are listed as
a Highly Cited Paper in the Essential Science Indicators (ESI),
have an H-index of 68, and have 130 000 citations. He was also
elected as “Highly Cited Chinese Researcher” by Elsevier for 5
consecutive years.
https://doi.org/10.1183/2312508X.10012124 vii
pneumonia in different settings and the risk factors associated with
antibiotic-resistant pathogens she has demonstrated that HIV
patients with Legionella pneumonia should be managed in the
same way as people without HIV and that virologically suppressed
HIV patients with pneumococcal pneumonia should be managed in
the same way as the general population and she has investigated
pneumonia and sepsis in very old patients.
Bin Cao
Bin Cao is Director of the Department of Pulmonary and Critical
Care Medicine, China-Japan Friendship Hospital (Beijing, China),
and a professor at Peking Union Medical College, Capital Medical
University, and Tsinghua University-Peking University Joint Center
for Life Sciences (all Beijing). He is a member of the Chinese
Academy of Medical Sciences, co-founder of CAP-China (https://
www.chinapneumonia.cn/) and President-Elect of Chinese Thoracic
Society (CTS). A physician-scientist, Bin is a leader in the field of
respiratory medicine and a tireless researcher of evidence-based
medicine for respiratory infections.
He pioneered “respiratory viral sepsis”, which extended the theory
of sepsis and initiated the “seven-category ordinal scale” in clinical
trials, which provided the feasibility to conduct randomised
controlled clinical trials during the pandemic. His research has an
outstanding influence in China and has provided a source for the
treatment guidelines of respiratory diseases of the WHO and around
the world.
Bin has published over 200 original peer reviewed articles and
reviews in major journals, including The Lancet and the New
England Journal of Medicine, among which 14 papers are listed as
a Highly Cited Paper in the Essential Science Indicators (ESI),
have an H-index of 68, and have 130 000 citations. He was also
elected as “Highly Cited Chinese Researcher” by Elsevier for 5
consecutive years.
https://doi.org/10.1183/2312508X.10012124 vii